Sign up now for ease of access to The Medical Independent, Ireland’s most frequently published medical newspaper, delivering award-winning news and investigative reporting.

  • receive the eCopy two days prior to the printed edition.
  • can partake in our online MCQs.
  • can enter our online sports quiz.


Medicalindependent.ie is Ireland's only investigative medical news website for doctors, healthcare professionals and anyone with an interest in health issues.

Established in 2010, along with its sister publication The Medical Independent, our stated aim is to investigate and analyse the major issues affecting healthcare and the medical profession in Ireland. The Medical Independent has won a number of awards for its investigative journalism, and its stories are frequently picked up by national digital, broadcast and print media. The Medical Independent is published by GreenCross Publishing.

Address: Top Floor, 111 Rathmines Road Lr, Dublin 6

Tel: 353 (01) 441 0024

GreenCross Publishing is owned by Graham Cooke.

AstraZeneca have issued updated safety notice

By Mindo - 02nd Jun 2021 | 40 views

Doctor injecting vaccine into arm of senior male patient

The manufacturers of Vaxzevria, the Covid-19 AstraZeneca vaccine, have issued updated safety advice on the risk of thrombosis in combination with thrombocytopenia.

In a notice to healthcare professionals on 2 June, AstraZeneca advised that individuals diagnosed with thrombocytopenia within three weeks of vaccination with Vaxzevria should be “actively investigated for signs of thrombosis”.

“Similarly, individuals who present with thrombosis within three weeks of vaccination should be evaluated for thrombocytopenia.”

The notice outlined that the vaccine is contraindicated in individuals who have experienced thrombosis with Thrombocytopenia Syndrome (TTS) following vaccination with Vaxzevria.

“TTS requires specialised clinical management. Healthcare professionals should consult applicable guidance and/or consult specialists (e.g., haematologists, specialists in coagulation) to diagnose and treat this condition.”

Use of Vaxzevria was temporarily suspended here for a short time amid concerns about rare but serious blood clotting events.

The suspension was later lifted with advice that it be given to the over 60s only. Current advice from the National Immunisation Advisory Committee (NIAC) states that: “mRNA vaccines are preferable for those aged under 50 years including those with medical conditions with very high or high risk of severe Covid-19 disease”.

The European Medicines Agency (EMA) estimates that TTS occurs in 1/100,000 people vaccinated with Vaxzevria.

According to NIAC, Preliminary UK evidence suggests that the risk of TTS may not be higher and is possibly substantially lower (1.6/ million) after a second dose of Vaxzevria. 

“Although most cases have been reported in females, this may be because more women have been vaccinated. Some TTS cases have been reported in men and further analysis is required to determine any sex-related risk,” states NIAC advice.

The latest safety notice from AstraZeneca notes that a combination of thrombosis and thrombocytopenia, in some cases accompanied by bleeding, has been very rarely observed following vaccination with Vaxzevria.

“This includes severe cases presenting as venous thrombosis, including in unusual sites, such as cerebral venous sinus thrombosis and splanchnic vein thrombosis, as well as arterial thrombosis, concomitant with thrombocytopenia. Some cases had a fatal outcome. The majority of these cases occurred in the first three weeks following vaccination and occurred mostly in women under 60 years of age.”

Leave a Reply

Latest
Latest Issue
medical news
The Medical Independent 19th May 2022

You need to be logged in to access this content. Please login or sign up using the links below.

Most Read